Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study : Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms:CoughFeverTiredSore throatDifficulty breathingRespiratory distressHeadacheLoss (or alteration) of smellLoss (or alteration) of sense of tasteMyalgiasChillsSubjective feverPink sputum (or coughing up blood)Thoracic painRunny noseAbdominal painNauseaVomitingDiarrheaConstipationIrritated or watery eyesRashesOther.
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 23. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 3, 2023, Last downloaded: ClinicalTrials.gov processed this data on January 31, 2024, Last updated: January 31, 2024 |
|---|
| Study ID: |
NCT05794412 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG009088105 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG009088105 | ||
| 003 | DE-627 | ||
| 005 | 20240131010540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230405s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG009088105 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05794412 | ||
| 035 | |a (UBBS_Klinische_Studien)2022-01722 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study |b Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 3, 2023, Last downloaded: ClinicalTrials.gov processed this data on January 31, 2024, Last updated: January 31, 2024 | ||
| 520 | |a The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms:CoughFeverTiredSore throatDifficulty breathingRespiratory distressHeadacheLoss (or alteration) of smellLoss (or alteration) of sense of tasteMyalgiasChillsSubjective feverPink sputum (or coughing up blood)Thoracic painRunny noseAbdominal painNauseaVomitingDiarrheaConstipationIrritated or watery eyesRashesOther | ||
| 650 | 2 | |a Infections | |
| 650 | 2 | |a Communicable Diseases | |
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Virus Diseases | |
| 650 | 2 | |a Respiratory Syncytial Virus Infections | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Active, not recruiting | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 23. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:01 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05794412 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 01 | ||